Replies to post #125707 on Biotech Values

[mcbio]

That is one patent. They have several.

Regardless of the patents, their latest 10Q says the following regarding their financial condition, which can't inspire a lot of confidence:

"As of March 31, 2011, we had cash and cash equivalents of $513,208. We anticipate that our existing capital resources will not enable us to continue operations beyond August 2011, or earlier if unforeseen events or circumstances arise that negatively affect our liquidity. If we fail to raise additional capital or obtain substantial cash inflows from potential partners prior to September 2011, we will be forced to cease operations. We are in discussions with several investors concerning our financing options. We cannot assure you that these discussions will result in available financing in a timely manner, on favorable terms or at all."

Have they done anything to alleviate their dire financial straits?

[masterlongevity]

I have a very strong opinion that none of their patents will hold up and that there will be ZERO royalties paid to them on bapineuzumab. At the most, Pfe/JNJ might pay them to go away, but not even sure about that.